These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19738023)

  • 21. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
    Fernández-Roblas R; Martín-de-Hijas NZ; Fernández-Martínez AI; García-Almeida D; Gadea I; Esteban J
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4184-6. PubMed ID: 18725441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicenter study.
    Casellas JM; Bantar C; Duret F;
    J Chemother; 2007 Oct; 19(5):482-7. PubMed ID: 18077902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.
    Edlund C; Nord CE
    Clin Microbiol Infect; 2000 Mar; 6(3):159-63. PubMed ID: 11168096
    [No Abstract]   [Full Text] [Related]  

  • 24. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient.
    Werner G; Gfrörer S; Fleige C; Witte W; Klare I
    J Antimicrob Chemother; 2008 May; 61(5):1182-3. PubMed ID: 18285315
    [No Abstract]   [Full Text] [Related]  

  • 25. A Snapshot of Co-Resistance to Carbapenems and Tigecycline in Clinical Isolates of Enterobacter cloacae.
    Huang LF; Lee CT; Su LH; Chang CL
    Microb Drug Resist; 2017 Jan; 23(1):1-7. PubMed ID: 27136494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
    Maraki S; Vardakas KZ; Samonis G; Perdikis D; Mavromanolaki VE; Kofteridis DP; Falagas ME
    Future Microbiol; 2017 Jun; 12():683-693. PubMed ID: 28540747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postantibiotic effect of tigecycline against 14 gram-positive organisms.
    Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2009 Feb; 53(2):782-4. PubMed ID: 19064899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First case of resistance to tigecycline by Klebsiella pneumoniae in a European University Hospital.
    Neonakis IK; Stylianou K; Daphnis E; Maraki S
    Indian J Med Microbiol; 2011; 29(1):78-9. PubMed ID: 21304206
    [No Abstract]   [Full Text] [Related]  

  • 30. [Susceptibility of Enterobacteriaceae rods to selected tetracyclines].
    Sekowska A; Ibsz-Fijałkowska A; Gołdyn K; Gospodarek E
    Med Dosw Mikrobiol; 2009; 61(4):321-6. PubMed ID: 20201321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro.
    Bax HI; Bakker-Woudenberg IA; Ten Kate MT; Verbon A; de Steenwinkel JE
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2577-9. PubMed ID: 26883697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.
    McAleese F; Petersen P; Ruzin A; Dunman PM; Murphy E; Projan SJ; Bradford PA
    Antimicrob Agents Chemother; 2005 May; 49(5):1865-71. PubMed ID: 15855508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.
    Thamlikitkul V; Tiengrim S
    J Antimicrob Chemother; 2008 Oct; 62(4):847-8. PubMed ID: 18567913
    [No Abstract]   [Full Text] [Related]  

  • 34. False non-susceptible results of tigecycline susceptibility testing against Enterobacteriaceae by an automated system: a multicentre study.
    Idelevich EA; Büsing M; Mischnik A; Kaase M; Bekeredjian-Ding I; Becker K
    J Med Microbiol; 2016 Aug; 65(8):877-881. PubMed ID: 27188162
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
    Henwood CJ; Gatward T; Warner M; James D; Stockdale MW; Spence RP; Towner KJ; Livermore DM; Woodford N
    J Antimicrob Chemother; 2002 Mar; 49(3):479-87. PubMed ID: 11864948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of Escherichia coli and Staphylococcus aureus isolates from a district general hospital in the U.K. to tigecycline and other antimicrobials.
    Chiriseri E; Minassian MA; Jenkins RO
    Br J Biomed Sci; 2010; 67(3):147-8. PubMed ID: 20973411
    [No Abstract]   [Full Text] [Related]  

  • 37. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
    Hope R; Mushtaq S; James D; Pllana T; Warner M; Livermore DM;
    J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
    Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation.
    Xie J; Wang T; Sun J; Chen S; Cai J; Zhang W; Dong H; Hu S; Zhang D; Wang X; Dong Y
    Int J Infect Dis; 2014 Jan; 18():62-7. PubMed ID: 24246741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in determining in vitro tigecycline susceptibility according to the agar medium used.
    Leal AL; Buitrago G; Ovalle MV; Cortés JA; Alvarez CA; Larrota J;
    J Chemother; 2010 Apr; 22(2):137-8. PubMed ID: 20435576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.